BioNTech SE (NASDAQ: BNTX)
Biotechnology · Mainz, Germany · Founded 2008
- Market capitalization: $25.0 billion
- Annual revenue: $4.0 billion
- Net income: $-0.5 billion
- Employees: 6,000
- Sector: Healthcare
- Headquarters: Mainz, Germany
- Founded: 2008
Source: Statvoo company profile for BioNTech SE. Browse all 500+ companies
BioNTech is a German biotechnology company that co-developed the first authorized COVID-19 vaccine with Pfizer. Founded by husband-and-wife team Uu011fur u015eahin and u00d6zlem Tu00fcreci, the company's core expertise is in mRNA technology and cancer immunotherapy. Before COVID, BioNTech was a little-known cancer research company. The pandemic transformed it into a household name and generated tens of billions in revenue.
COVID vaccine revenue (shared with Pfizer) was the dominant revenue source, generating over u20ac17 billion in 2022 alone. The company is now investing heavily in oncology (individualized cancer vaccines, CAR-T therapies) and infectious disease vaccines. BioNTech's pipeline includes over 30 clinical programs. The company is spending its COVID windfall on R&D and acquisitions to build a diversified pipeline.
u015eahin and Tu00fcreci founded BioNTech in Mainz, Germany in 2008, focused on personalized cancer immunotherapy. The company went public on the Nasdaq in October 2019 at $15 per share u2014 just months before COVID changed everything. u015eahin read about the Wuhan outbreak in January 2020 and immediately redirected the company's mRNA platform to develop a vaccine. The Pfizer partnership was announced in March 2020.
| Market Capitalization | $25.0B |
| Annual Revenue | $4.0B |
| Net Income | $-0.5B |
| Profit Margin | -12% |
| Revenue per Employee | $666667K |
| Stock Exchange | NASDAQ |
| Ticker Symbol | BNTX |
Financial data is approximate and based on most recent annual filings.
u015eahin and Tu00fcreci are both children of Turkish immigrants to Germany. They reportedly spent their wedding day in the lab. BioNTech's COVID vaccine was codenamed "Project Lightspeed." The company went from a $3.4 billion market cap at IPO to over $100 billion at its peak. u015eahin still rides a bicycle to work at BioNTech's Mainz headquarters.
BioNTech has the cash and the science to become a major oncology player, but the transition from COVID windfall to sustainable cancer drug revenue is a multi-year journey with no guaranteed outcome.
What is BioNTech SE's revenue?
BioNTech SE generates approximately $4.0 billion in annual revenue.
How many employees does BioNTech SE have?
BioNTech SE employs approximately 6,000 people worldwide.
What is BioNTech SE's market cap?
BioNTech SE (BNTX) has a market capitalization of approximately $25.0 billion on the NASDAQ.
When was BioNTech SE founded?
BioNTech SE was founded in 2008 and is headquartered in Mainz, Germany.
Who is the CEO of BioNTech SE?
Ugur Sahin is the current CEO of BioNTech SE.
What is BioNTech SE's website?
BioNTech SE's official website is biontech.com.
| CEO | Ugur Sahin |
| Sector | Healthcare |
| Industry | Biotechnology |
| Founded | 2008 |
| HQ | Mainz |
| Country | Germany |
| Website | biontech.com |
See traffic, security, and technical data for BioNTech SE's website:
📊 biontech.com stats 📋 WHOIS 🌐 DNS 🔒 SSL